Kimberly Woodliff
Acute Care · Waco, TXNPI 1699309393
Payments from drug & device makers
Across 155 payments — averaging $40.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$2K
- AstraZeneca$1K
- Regeneron Healthcare Solutions, Inc.$645
- GSK$463
- Actelion Pharmaceuticals US, Inc.$437
- Phathom Pharmaceuticals, Inc.$211
- plus $998 from 12 others
What the payments were for
- Consulting fees$73212%
- Food & beverage$4,89979%
- Education$5769%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 30 | $2,088 |
| AstraZeneca | 36 | $1,366 |
| Regeneron Healthcare Solutions, Inc. | 20 | $645 |
| GSK | 23 | $463 |
| Actelion Pharmaceuticals US, Inc. | 8 | $437 |
| Phathom Pharmaceuticals, Inc. | 13 | $211 |
| Sanofi-aventis U.S. LLC | 2 | $179 |
| Amgen | 4 | $149 |
| Pfizer | 4 | $139 |
| Inspire Medical Systems, Inc. | 1 | $114 |
| Edwards Lifesciences | 1 | $107 |
| Fisher & Paykel Healthcare Inc | 2 | $97 |
| ANI Pharmaceuticals, Inc. | 3 | $56 |
| Boehringer Ingelheim | 1 | $50 |
| United Therapeutics Corporation | 2 | $34 |
| Philips North America LLC | 2 | $29 |
| Electromed, Inc. | 2 | $28 |
| Verona Pharma, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,207 in reported general payments places this provider in the 95th percentile of 2,323 acute care providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 608 | $476,250 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 291 | $215,492 |
| Breo ElliptaFluticasone/Vilanterol | 197 | $91,946 |
| Dupixent PenDupilumab | 20 | $74,369 |
| Spiriva RespimatTiotropium Bromide | 53 | $30,345 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 40 | $29,662 |
| Incruse ElliptaUmeclidinium Bromide | 63 | $21,572 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 47 | $20,994 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 35 | $19,130 |
| EliquisApixaban | 22 | $18,953 |
| SymbicortBudesonide/Formoterol Fumarate | 48 | $13,551 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 462 | $11,262 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 91 | $10,555 |
| XareltoRivaroxaban | 12 | $9,781 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 18 | $8,711 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $463 | $626,219933 claims |
| AstraZenecaBreztri Aerosphere, Bevespi Aerosphere, Symbicort | $1,366 | $248,172374 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat | $50 | $60,050118 claims |
| PfizerEliquis | $139 | $18,95322 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $56 | $24226 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,323 acute care providers in Texas.
Other acute care in Waco
- Jennifer PilotteDallas$232K
- Christie MorrisonSan Antonio$225K
- Amanda BradleyDallas$85K
- Laura WilsonEl Paso$32K
- Kim HuynhCypress$29K
- Martha LibertyDallas$28K
- Afton DickersonHouston$27K
- Eleanor WeltgeHouston$25K
- Leslie GutierrezHouston$25K
- Bahia ElkamandSugar Land$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.